3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
12
Recruiting
10
Active not recruiting
9
Not yet recruiting
6
Unknown
5
Terminated
3
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
1
Infiltrating Bladder Urothelial Carcinoma
1
Carcinoma, Transitional Cell
1
Interventions
tremelimumab
4
Cystoscopy
3
durvalumab
2
avelumab
2
Paclitaxel
2
Gemcitabine
2
Docetaxel
2
Cisplatin
2
vocimagene amiretrorepvec
1
vinflunine
1
trebananib
1
trastuzumab duocarmazine
1
pegfilgrastim
1
merphos
1
infigratinib
1
erdafitinib
1
efineptakin alfa
1
copanlisib
1
atezolizumab
1
Vinblastine
1
Trastuzumab
1
Taxes
1
TAS-116
1
Specimen Handling
1
Sirolimus
1
Rosiglitazone
1
Ropivacaine
1
Rogaratinib
1
Radiotherapy
1
Polymerase Chain Reaction
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Urinary Bladder Neoplasms
×
Cystectomy
×
Clear all
NCT02845050
2018-02-13
JaNEO
Ligartis GmbH
Phase 1/2
Withdrawn